Quantcast

Latest AbbVie Stories

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-09 12:28:04

- Only 28% of Parkinson's patients are currently receiving care from a Parkinson's specialist NEW YORK, Sept. 9, 2014 /PRNewswire-USNewswire/ -- A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatment and in the Parkinson's community. http://photos.prnewswire.com/prnvar/20140909/144393 "When patients get to the right doctor, it...

2014-09-03 12:32:05

- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer. Calico is the...

2014-08-18 12:27:32

- Recipients will compete for public votes for a chance to win one of two Thriving Undergraduate and Graduate Scholar awards NORTH CHICAGO, Ill., Aug. 18, 2014 /PRNewswire/ -- AbbVie today announced the 40 outstanding students with cystic fibrosis (CF) who will each receive $2,500 to pursue their undergraduate or graduate school education during the 2014-2015 school year through the AbbVie CF Scholarship program. Voting for two of the 40 winners to earn the title of 2014 Thriving...

2014-08-04 08:27:33

- Results from Phase I program in glioblastoma multiforme presented at ASCO earlier this year NORTH CHICAGO, Ill., Aug. 4, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with...

2014-08-01 12:25:54

- AbbVie will donate $10 to Cystic Fibrosis Research, Inc. (CFRI) for every recipe collected between August 1 and September 15, 2014, up to $10,000 NORTH CHICAGO, Ill. and PALO ALTO, Calif., Aug. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a partnership to expand awareness of proper nutritional habits in the cystic fibrosis (CF) community through the CFChef Shares program. CFChef Shares will run from August 1 to September...

2014-07-22 12:30:17

Initiative to optimize patient care spearheaded by AbbVie and The Michael J. Fox Foundation to visit 11 cities in 2014 NEW YORK, July 22, 2014 /PRNewswire-USNewswire/ -- National Parkinson's organizations are working together to help provide Parkinson's patients and caregivers with knowledge and support to optimize their care through the "Partners in Parkinson's" strategic health initiative launched by The Michael J. Fox Foundation and AbbVie. Partners in Parkinson's offers...

2014-06-26 08:27:43

- Trial will measure investigational compound's efficacy and safety in patients with HER2-negative breast cancer, associated with BRCA 1, BRCA 2 mutations NORTH CHICAGO, Ill., June 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related